Economy/Home · Economy

ImmunOncia Receives MFDS Approval for Amendment to Phase 1 Clinical Trial Plan of IMC-002... Pancreatic Ductal Adenocarcinoma (PDAC) Cohort Added

ImmunOncia announced that it has received approval from the Ministry of Food and Drug Safety (MFDS) for an amendment to the Phase 1 clinical trial plan of IMC-002. According to the regulatory filing, the approval date for the amendment was August 4, 2026. ImmunOncia had submitted the application fo

Oseong Kwon
Staff Reporter
4 min read
ImmunOncia Receives MFDS Approval for Amendment to Phase 1 Clinical Trial Plan of IMC-002... Pancreatic Ductal Adenocarcinoma (PDAC) Cohort Added
CBC News

ImmunOncia announced that it has received approval from the Ministry of Food and Drug Safety (MFDS) for an amendment to the Phase 1 clinical trial plan of IMC-002.

According to the regulatory filing, the approval date for the amendment was August 4, 2026. ImmunOncia had submitted the application for the amendment on July 1. With this approval, a pancreatic ductal adenocarcinoma (PDAC) cohort has been added to the Part 2 expansion cohort of the Phase 1 clinical trial of IMC-002.

■ Clinical Trial Design

The trial is an open-label, dose-escalation and expansion Phase 1 clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of IMC-002 in patients with advanced cancer who have failed standard therapy. It is being conducted at Samsung Medical Center, Asan Medical Center, and the National Cancer Center in South Korea.

In terms of dosing, Part 1 administers IMC-002 at doses of 5, 10, 20, and 30 mg/kg every two weeks. In the Part 2 expansion cohort, patients receive IMC-002 at 20 mg/kg followed by combination with standard of care (SOC).

Approximately 12 subjects will be enrolled in each disease cohort, and depending on the review of safety and other factors, the number of subjects per cohort may be increased to a maximum of 18.

■ Evaluation Objectives

The primary objective of the trial is to evaluate the safety and tolerability of IMC-002 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Secondary objectives include evaluating the pharmacokinetic profile and preliminary antitumor activity.

■ Expected Completion Schedule

The expected completion date of the clinical trial stated in the regulatory filing is March 31, 2030. The company explained that this date is the estimated completion date specified in the clinical trial plan application and may be subject to change. It also added that the clinical trial sites may be changed depending on the circumstances of the institutions.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.